Aclarion vs Sera Prognostics
ACON and SERA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACON and SERA compare
Sera Prognostics is the larger company, worth 16 times as much as Aclarion ($76.5M against $4.7M).
Aclarion grew revenue faster over the last twelve months (46.0% versus 1.1% for Sera Prognostics).
Aclarion keeps more of each dollar of sales as profit, with a net margin of −10260% compared with −34867% at Sera Prognostics.
Aclarion scores higher on the StockData Score (8 against 5 for Sera Prognostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACON | SERA |
|---|---|---|
| Size and price | ||
| Market cap | $4.7M | $76.5M |
| Share price | $1.63 | $1.94 |
| Change, 1 year | −77.5% | −23.9% |
| Change, 5 years | – | −82.0% |
| Beta (5Y) | 0.77 | 1.23 |
| Employees | 11 | – |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.7× (better) | 797× |
| P/B | 0.3× (better) | 1.5× |
| FCF yield | – | −37.9% |
| Growth | ||
| Revenue growth (TTM) | 46.0% (better) | 1.1% |
| Revenue growth, 5Y average | – | 26.5% |
| Profitability | ||
| Gross margin | 29.1% | – |
| Operating margin | −10789% (better) | −38755% |
| Net margin | −10260% (better) | −34867% |
| FCF margin | – | −30199% |
| Return on equity | −74.1% | −49.7% (better) |
| Return on invested capital | −959% | −124% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −5315.0× |
| Current ratio | 14.17 (better) | 1.88 |
| Altman Z-score | −4.34 (better) | −5.45 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −33.4% | 0.00% (better) |
| Shareholder yield | −33.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 9.0% | 43.2% |
| Held by insiders | 16.4% | 30.4% |
| Insider net buying, 12 months | $177K (better) | −$524K |
| Short interest, % of float | – | 0.80% |
Go deeper
- ACON stock overview
- ACON income statement
- ACON valuation and score
- SERA stock overview
- SERA income statement
- SERA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.